Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: US FDA happy to review anal fissure drug; gives green light to Clarity’s Phase 3 trial
Health & Biotech
PharmAust’s preliminary trial data indicate slowing or stopping the progression of motor neuron loss that causes MND
News
Closing Bell: ASX scores in closing minutes of EOFY trade to finish in the green after volatile day
Health & Biotech
PharmAust gives patients in Motor Neurone Disease clinical trial escalated dose ahead of Phase-2
Health & Biotech
PharmAust begins Cohort 3 dosing in Phase 1/2 motor neurone disease trial
Health & Biotech
PharmAust flags ‘steady state’ levels in Motor Neurone Disease clinical trial
Health & Biotech
PharmAust confirms safety of MPL, poised to up dosage in MND trial
News
In Case You Missed It: Lithium, rare earth and pharma players do the heavy lifting
Health & Biotech
mTOR drug shows reverse ageing may be possible. Here’s where it puts ASX-listed PharmAust
Health & Biotech
PharmAust’s interim analysis to point the way forward for MND trial
Health & Biotech
PharmAust says its MPL drug has a long and stable shelf life
News
Market Highlights: Wall Street sweat on debt ceiling, CPI; and 5 ASX small caps to watch today
Health & Biotech
ASX Health Stocks: The US FDA will pay a visit to Cyclopharm’s facility in NSW
Health & Biotech
PharmAust’s MPL drug shows anti-cancer effects across multiple cancer types
News
Market Highlights: Markets brace for more headwinds, and 5 ASX small caps to watch on Tuesday
Health & Biotech
PharmAust’s oversubscribed $2.5m placement highlights investor backing
Health & Biotech
